Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
9.34
+0.53 (6.02%)
Aug 13, 2025, 4:00 PM - Market closed
Tempest Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Tempest Therapeutics stock have a consensus rating of "Hold" and an average price target of $30, which forecasts a 221.20% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $65.
Price Target: $30 (+221.20%)
Analyst Consensus: Hold
* Price targets were last updated on Apr 10, 2025.
Analyst Ratings
The average analyst rating for Tempest Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy → Hold Downgrades $91 → $9 | Buy → Hold | Downgrades | $91 → $9 | -3.64% | Apr 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $16 | Strong Buy → Hold | Downgrades | $16 | +71.31% | Apr 10, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $169 → $91 | Buy | Maintains | $169 → $91 | +874.30% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $611 → $208 | Strong Buy | Maintains | $611 → $208 | +2,126.98% | Mar 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $104 → $65 | Buy | Maintains | $104 → $65 | +595.93% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-10.33
from -19.50
EPS Next Year
-10.59
from -10.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.85 | -4.98 | -14.00 | ||
| Avg | -10.33 | -10.59 | -13.60 | ||
| Low | -12.52 | -15.70 | -13.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.